Eikon Therapeutics, Inc. (EIKN) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$8.70

From 52W high−44.96%

Volume2.20M

Market cap$484.78M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$8.70

From 52W high

−44.96%

Volume

2.20M

Market cap

$484.78M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.7x

P/E (TTM)

—

RSI (14)

40.0

MomentumView details →

1D Return

+4.07%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−69.06%

ROA (TTM)

−41.33%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+4.07%

YTD Return

—

1Y Return

—

RSI (14)

40.0

vs 50D SMA

−12.69%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.54x

Current Ratio

9.89x

Quick Ratio

9.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.63

EPS Surprise

−3.16%

Beats (12Q)

0/12

Next Q EPS Est

−$1.70

Avg Surprise (4Q)

−28.46%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−322.16M

Op. CF (TTM)

−256.02M

Next earningsNov 12, 2026 →

Latest newsMore news →

Eikon Therapeutics reported its financial results for the second quarter of 2026 and provided clinical program updates on August 13, 2026.38d ago

Ma. Fatima D. Francisco was appointed as a Class I director and member of the Compensation Committee of Eikon Therapeutics, Inc., effective June 15, 2026, with an option to purchase 85,937 shares of common stock at $8.96 per share vesting in 48 equal monthly installments.103d ago

Similar companies

Vogenx Inc.VOGX Puma Biotechnology, Inc.PBYI Indaptus Therapeutics, Inc.INDP XOMA Royalty Corp.XOMA MapLight Therapeutics, Inc.MPLT Assembly Biosciences, Inc.ASMB Find similar companies →

Latest newsMore news →

Eikon Therapeutics reported its financial results for the second quarter of 2026 and provided clinical program updates on August 13, 2026.38d ago Ma. Fatima D. Francisco was appointed as a Class I director and member of the Compensation Committee of Eikon Therapeutics, Inc., effective June 15, 2026, with an option to purchase 85,937 shares of common stock at $8.96 per share vesting in 48 equal monthly installments.103d ago